Clinical Efficacy and Safety of Afatinib in the Treatment of Non-Small-Cell Lung Cancer in Chinese Patients

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s136579
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Observational Study on the Efficacy and Safety of Erlotinib in Patients With Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2012English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results From SWOG S1403

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy